HR 756, a new cephalosporin active against gram-positive and gram-negative aerobic and anaerobic bacteria.
The in vitro activity of HR 756, 7-[2-(2-amino-4-thiazolyl)-2-(Z)-(methoximino)acetamido] cephalosporanic acid, was investigated against 659 isolates. HR 756 inhibited Neisseria and Haemophilus species at concentrations similar to those needed with ampicillin. It inhibited beta-lactamase-producing N. gonorrhoeae and H. influenzae. HR 756 was the most active compound tested against members of the Enterobacteriaceae, inhibiting most isolates of Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Salmonella, Enterobacter, and Shigella at concentrations of less than 0.1 mug/ml. It was twice as active as carbenicillin against Pseudomonas aeruginosa and inhibited Bacteroides fragilis as well as cefoxitin. HR 756 killed E. coli, Staphylococcus aureus, and P. aeruginosa at rates similar to other beta-lactam antibiotics.
D000332:Aerobiosis; D000693:Anaerobiosis; D001419:Bacteria / Q000187:drug effects*; D002510:Cephalosporinase / Q000378:metabolism; D002511:Cephalosporins / Q000378:metabolism / Q000494:pharmacology*; D004357:Drug Synergism; D006801:Humans; D008826:Microbial Sensitivity Tests; D011485:Protein Binding; D013997:Time Factors
D002511:Cephalosporins; D002510:Cephalosporinase